Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: adalimumab
DATE: 16/08/2018
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
